Vision Preservation and Restoration Following a 6 Month Trial of GlaucoCetin
Primary Open Angle Glaucoma
About this trial
This is an interventional treatment trial for Primary Open Angle Glaucoma focused on measuring primary open angle glaucoma, visual field loss, vision enhancement, GlaucoCetin, Neuroprotection
Eligibility Criteria
Inclusion Criteria:
- Age of 40 to 80 years
Bilateral open angle glaucoma with reliable visual field defects (at least one eye with mean deviation (MD) between -4.00 to -10.00 decibels (dB) on Humphrey Visual Field 24-2.
- Group 1 (Peripheral): meets 1 hodapp-parrish-anderson (HPA) criteria for defect (3 contiguous points depressed on the pattern standard deviation (PSD) p <5%, one of which is depressed at p <1% level), and does not meet below paracentral criteria for Group 2.
- Group 2 (Central): at least 1 paracentral point repeatedly depressed at p<1% on 24-2. Also meets the HAP criteria outlined above.
- Visual acuity 20/40 or better in each eye
- Intraocular Pressure (IOP) controlled at 2 measurements >3 months
- Clear media
Exclusion Criteria:
- Known bleeding disorder
- History of epilepsy or on anti-seizure medication
- Uncontrolled hypertension or diabetes
- Uncontrolled IOP
- Eye pathology leading to inaccurate IOP measurement
- Visually significant retinal pathology affecting vision in past or active (such as diabetic retinopathy or age related macular degeneration)
- Non-glaucomatous optic neuropathy
- Visually significant cataract (worse then 2+ cataract, or what is determined visually clinically significant by physician)
- History of ocular trauma
- Selective laser trabeculoplasty or laser procedure within past 3 months
- Cataract surgery within past 3 months
- Incisional glaucoma surgery within 6 months
- Current use of nitroglycerin
- Current use of antiplatelet therapy besides aspirin (such as clopidogrel) or anticoagulation (such as warfarin)
- Current use of systemic steroids or immunomodulating agents such as methotrexate.
- Sensitivity or allergy to any ingredients in GlaucoCetin: Curcumin, L-Taurine, N-Acetyl Cysteine, Niacinamide, Ginkgo Biloba, Lipoic Acid, Citicoline, Grape Seed Extract, Green Tea Leaf Extract, Coenzyme Q10, Biotin, Natural Astaxanthin, flavonoid complex containing Fisetin, Quercetin, and Luteolin
- Recent change in systemic medications or vitamins
- Use of Biotin, Ginkgo Biloba, Citicoline within past 3 months (or any other Glaucocetin ingredients within 1 month)
- Unreliable visual fields
- Unwilling to take supplement or placebo for 6 months
Sites / Locations
- Wills Eye Hospital, Glaucoma Research CenterRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Active Comparator
Placebo Comparator
Active Comparator
Placebo Comparator
GlaucoCetin Peripheral Group
Placebo Peripheral Group
GlaucoCetin Central Group
Placebo Central Group
Primary Open Angle Glaucoma participants who meet inclusion exclusion criteria with peripheral visual field loss will be randomly assigned GlaucoCetin, a medical food in capsule form.
Primary Open Angle Glaucoma participants who meet inclusion exclusion criteria with peripheral visual field loss will be randomly assigned a placebo, with no nutritional value, in capsule form.
Primary Open Angle Glaucoma participants who meet inclusion exclusion criteria with central visual field loss will be randomly assigned GlaucoCetin, a medical food in capsule form.
Primary Open Angle Glaucoma participants who meet inclusion exclusion criteria with central visual field loss will be randomly assigned a placebo, with no nutritional value, in capsule form.